Increased expression of Mer tyrosine kinase in circulating dendritic cells and monocytes of lupus patients:Correlations with plasma interferon activity and steroid therapy

Arthritis Research and Therapy

Volumn 16, Issue 2, 2014, Pages

  Hilliard, Brendan A ^a   Zizzo, Gaetano ^a   Ulas, Mehriban ^a   Linan, Margaret K ^b   Schreiter, Jessica ^c   Cohen, Philip L ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TEMPLE UNIVERSITY   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; INTERFERON STIMULATED GENE FACTOR 3; MER TYROSINE KINASE; PREDNISONE; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; ADRENAL CORTEX HORMONES; INTERFERON TYPE I; MERTK PROTEIN, HUMAN; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; LEUKOCYTE; MALE; MONOCYTE; MYELOID DENDRITIC CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMACYTOID DENDRITIC CELL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SLEDAI; STEROID THERAPY; SYSTEMIC LUPUS ERYTHEMATOSUS; BIOSYNTHESIS; BLOOD; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; METABOLISM; MIDDLE AGED; MONOCYTES;

ADRENAL CORTEX HORMONES; ADULT; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; INTERFERON TYPE I; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MONOCYTES; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84897550342     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4517     Document Type: Article

References (61)

1. Lai C, Lemke G. An extended family of protein-tyrosine kinase genes differentially expressed in the vertebrate nervous system. Neuron 1991, 6:691-704. 10.1016/0896-6273(91)90167-X, 2025425.
2. Lemke G, Burstyn-Cohen T. TAM receptors and the clearance of apoptotic cells. Ann N Y Acad Sci 2010, 1209:23-29. 10.1111/j.1749-6632.2010.05744.x, 3061224, 20958312.
3. Scott RS, McMahon EJ, Pop SM, Reap EA, Caricchio R, Cohen PL, Earp HS, Matsushima GK. Phagocytosis and clearance of apoptotic cells is mediated by MER. Nature 2001, 411:207-211. 10.1038/35075603, 11346799.
4. Anderson HA, Maylock CA, Williams JA, Paweletz CP, Shu H, Shacter E. Serum-derived protein S binds to phosphatidylserine and stimulates the phagocytosis of apoptotic cells. Nat Immunol 2003, 4:87-91.
5. Lu Q, Lemke G. Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family. Science (New York) 2001, 293:306-311.
6. Rothlin CV, Lemke G. TAM receptor signaling and autoimmune disease. Curr Opin Immunol 2010, 22:740-746. 10.1016/j.coi.2010.10.001, 2997887, 21030229.
7. Sen P, Wallet MA, Yi Z, Huang Y, Henderson M, Mathews CE, Earp HS, Matsushima G, Baldwin AS, Tisch RM. Apoptotic cells induce Mer tyrosine kinase-dependent blockade of NF-kappaB activation in dendritic cells. Blood 2007, 109:653-660. 10.1182/blood-2006-04-017368, 1785106, 17008547.
8. Shao WH, Zhen Y, Rosenbaum J, Eisenberg RA, McGaha TL, Birkenbach M, Cohen PL. A protective role of Mer receptor tyrosine kinase in nephrotoxic serum-induced nephritis. Clin Immunol (Orlando) 2010, 136:236-244.
9. Sharif MN, Sosic D, Rothlin CV, Kelly E, Lemke G, Olson EN, Ivashkiv LB. Twist mediates suppression of inflammation by type I IFNs and Axl. J Exp Med 2006, 203:1891-1901. 10.1084/jem.20051725, 2118370, 16831897.
10. Neubauer A, Fiebeler A, Graham DK, O'Bryan JP, Schmidt CA, Barckow P, Serke S, Siegert W, Snodgrass HR, Huhn D. Expression of axl, a transforming receptor tyrosine kinase, in normal and malignant hematopoiesis. Blood 1994, 84:1931-1941.
11. Scutera S, Fraone T, Musso T, Cappello P, Rossi S, Pierobon D, Orinska Z, Paus R, Bulfone-Paus S, Giovarelli M. Survival and migration of human dendritic cells are regulated by an IFN-alpha-inducible Axl/Gas6 pathway. J Immunol 2009, 183:3004-3013. 10.4049/jimmunol.0804384, 19657094.
12. Seitz HM, Camenisch TD, Lemke G, Earp HS, Matsushima GK. Macrophages and dendritic cells use different Axl/Mertk/Tyro3 receptors in clearance of apoptotic cells. J Immunology 2007, 178:5635-5642.
13. Kazeros A, Harvey BG, Carolan BJ, Vanni H, Krause A, Crystal RG. Overexpression of apoptotic cell removal receptor MERTK in alveolar macrophages of cigarette smokers. Am J Respir Cell Mol Biol 2008, 39:747-757. 10.1165/rcmb.2007-0306OC, 2586050, 18587056.
14. Guignant C, Venet F, Planel S, Demaret J, Gouel-Cheron A, Nougier C, Friggeri A, Allaouchiche B, Lepape A, Monneret G. Increased MerTK expression in circulating innate immune cells of patients with septic shock. Intensive Care Med 2013, 39:1556-1564. 10.1007/s00134-013-3006-9, 23835724.
15. Strick DJ, Feng W, Vollrath D. Mertk drives myosin II redistribution during retinal pigment epithelial phagocytosis. Invest Ophthalmol Vis Sci 2009, 50:2427-2435. 10.1167/iovs.08-3058, 19117932.
16. Kuenkele S, Beyer TD, Voll RE, Kalden JR, Herrmann M. Impaired clearance of apoptotic cells in systemic lupus erythematosus:challenge of T and B cell tolerance. Curr Rheumatol Rep 2003, 5:175-177. 10.1007/s11926-003-0061-1, 12744807.
17. Baumann I, Kolowos W, Voll RE, Manger B, Gaipl U, Neuhuber WL, Kirchner T, Kalden JR, Herrmann M. Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus. Arthritis Rheum 2002, 46:191-201. 10.1002/1529-0131(200201)46:1<191::AID-ART10027>3.0.CO;2-K, 11817590.
18. Ren Y, Tang J, Mok MY, Chan AW, Wu A, Lau CS. Increased apoptotic neutrophils and macrophages and impaired macrophage phagocytic clearance of apoptotic neutrophils in systemic lupus erythematosus. Arthritis Rheum 2003, 48:2888-2897. 10.1002/art.11237, 14558095.
19. Tas SW, Quartier P, Botto M, Fossati-Jimack L. Macrophages from patients with SLE and rheumatoid arthritis have defective adhesion in vitro, while only SLE macrophages have impaired uptake of apoptotic cells. Ann Rheum Dis 2006, 65:216-221. 10.1136/ard.2005.037143, 1798004, 16014673.
20. Herrmann M, Voll RE, Zoller OM, Hagenhofer M, Ponner BB, Kalden JR. Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum 1998, 41:1241-1250. 10.1002/1529-0131(199807)41:7<1241::AID-ART15>3.0.CO;2-H, 9663482.
21. Lu L, Kaliyaperumal A, Boumpas DT, Datta SK. Major peptide autoepitopes for nucleosome-specific T cells of human lupus. J Clin Invest 1999, 104:345-355. 10.1172/JCI6801, 408421, 10430616.
22. Gheita TA, Bassyouni IH, Bassyouni RH. Plasma concentrations of growth arrest specific protein 6 and the soluble form of its tyrosine kinase receptor Axl in patients with systemic lupus erythematosus and Behcets disease. J Clin Immunol 2012, 32:1279-1286. 10.1007/s10875-012-9743-7, 22833165.
23. Recarte-Pelz P, Tassies D, Espinosa G, Hurtado B, Sala N, Cervera R, Reverter JC, de Frutos PG. Vitamin K-dependent proteins GAS6 and protein S and TAM receptors in patients of systemic lupus erythematosus:correlation with common genetic variants and disease activity. Arthritis Res Ther 2013, 15:R41. 10.1186/ar4199, 3672795, 23497733.
24. Suh CH, Hilliard B, Li S, Merrill JT, Cohen PL. TAM receptor ligands in lupus:protein S but not Gas6 levels reflect disease activity in systemic lupus erythematosus. Arthritis Res Ther 2010, 12:R146. 10.1186/ar3088, 2945040, 20637106.
25. Wu J, Ekman C, Jonsen A, Sturfelt G, Bengtsson AA, Gottsater A, Lindblad B, Lindqvist E, Saxne T, Dahlback B. Increased plasma levels of the soluble Mer tyrosine kinase receptor in systemic lupus erythematosus relate to disease activity and nephritis. Arthritis Res Ther 2011, 13:R62. 10.1186/ar3316, 3132057, 21496228.
26. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI, a disease activity index for lupus patients:The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992, 35:630-640. 10.1002/art.1780350606, 1599520.
27. Ziegler-Heitbrock L, Ancuta P, Crowe S, Dalod M, Grau V, Hart DN, Leenen PJ, Liu YJ, MacPherson G, Randolph GJ, Scherberich J, Schmitz J, Shortman K, Sozzani S, Strobl H, Zembala M, Austyn JM, Lutz MB. Nomenclature of monocytes and dendritic cells in blood. Blood 2010, 116:e74-e80. 10.1182/blood-2010-02-258558, 20628149.
28. Cros J, Cagnard N, Woollard K, Patey N, Zhang SY, Senechal B, Puel A, Biswas SK, Moshous D, Picard C, Jais JP, D'Cruz D, Casanova JL, Trouillet C. Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity 2010, 33:375-386. 10.1016/j.immuni.2010.08.012, 3063338, 20832340.
29. Sather S, Kenyon KD, Lefkowitz JB, Liang X, Varnum BC, Henson PM, Graham DK. A soluble form of the Mer receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation. Blood 2007, 109:1026-1033. 1785151, 17047157.
30. Ytterberg SR, Schnitzer TJ. Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum 1982, 25:401-406. 10.1002/art.1780250407, 6176248.
31. Behrens EM, Gadue P, Gong SY, Garrett S, Stein PL, Cohen PL. The Mer receptor tyrosine kinase:expression and function suggest a role in innate immunity. Eur J Immunol 2003, 33:2160-2167. 10.1002/eji.200324076, 12884290.
32. Shao WH, Zhen Y, Eisenberg RA, Cohen PL. The Mer receptor tyrosine kinase is expressed on discrete macrophage subpopulations and mainly uses Gas6 as its ligand for uptake of apoptotic cells. Clin Immunol (Orlando) 2009, 133:138-144.
33. Zahuczky G, Kristof E, Majai G, Fesus L. Differentiation and glucocorticoid regulated apopto-phagocytic gene expression patterns in human macrophages:role of Mertk in enhanced phagocytosis. PLoS One 2011, 6:e21349. 10.1371/journal.pone.0021349, 3123306, 21731712.
34. Zizzo G, Hilliard BA, Monestier M, Cohen PL. Efficient clearance of early apoptotic cells by human macrophages requires M2c polarization and MerTK induction. J Immunology 2012, 189:3508-3520.
35. Ziegler-Heitbrock L, Hofer TP. Toward a refined definition of monocyte subsets. Front Immunol 2013, 4:23. 3562996, 23382732.
36. Scherberich JE, Nockher WA. CD14++ monocytes, CD14+/CD16+ subset and soluble CD14 as biological markers of inflammatory systemic diseases and monitoring immunosuppressive therapy. Clin Chem Lab Med 1999, 37:209-213.
37. Skrzeczynska-Moncznik J, Bzowska M, Loseke S, Grage-Griebenow E, Zembala M, Pryjma J. Peripheral blood CD14high CD16+ monocytes are main producers of IL-10. Scand J Immunol 2008, 67:152-159. 10.1111/j.1365-3083.2007.02051.x, 18201370.
38. Wong KL, Tai JJ, Wong WC, Han H, Sem X, Yeap WH, Kourilsky P, Wong SC. Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets. Blood 2011, 118:e16-e31. 10.1182/blood-2010-12-326355, 21653326.
39. Rossol M, Kraus S, Pierer M, Baerwald C, Wagner U. The CD14(bright) CD16+ monocyte subset is expanded in rheumatoid arthritis and promotes expansion of the Th17 cell population. Arthritis Rheum 2012, 64:671-677. 10.1002/art.33418, 22006178.
40. Rogacev KS, Seiler S, Zawada AM, Reichart B, Herath E, Roth D, Ulrich C, Fliser D, Heine GH. CD14++CD16+ monocytes and cardiovascular outcome in patients with chronic kidney disease. Eur Heart J 2011, 32:84-92. 10.1093/eurheartj/ehq371, 20943670.
41. Heine GH, Ulrich C, Seibert E, Seiler S, Marell J, Reichart B, Krause M, Schlitt A, Kohler H, Girndt M. CD14(++)CD16+ monocytes but not total monocyte numbers predict cardiovascular events in dialysis patients. Kidney Int 2008, 73:622-629. 10.1038/sj.ki.5002744, 18160960.
42. Rogacev KS, Cremers B, Zawada AM, Seiler S, Binder N, Ege P, Grosse-Dunker G, Heisel I, Hornof F, Jeken J, Rebling NM, Ulrich C, Scheller B, Böhm M, Fliser D, Heine GH. CD14++CD16+ monocytes independently predict cardiovascular events:a cohort study of 951 patients referred for elective coronary angiography. J Am Coll Cardiol 2012, 60:1512-1520. 10.1016/j.jacc.2012.07.019, 22999728.
43. Mikolajczyk TP, Skrzeczynska-Moncznik JE, Zarebski MA, Marewicz EA, Wisniewska AM, Dzieba M, Dobrucki JW, Pryjma JR. Interaction of human peripheral blood monocytes with apoptotic polymorphonuclear cells. Immunology 2009, 128:103-113. 10.1111/j.1365-2567.2009.03087.x, 2747143, 19689740.
44. Yi Z, Li L, Matsushima GK, Earp HS, Wang B, Tisch R. A novel role for c-Src and STAT3 in apoptotic cell-mediated MerTK-dependent immunoregulation of dendritic cells. Blood 2009, 114:3191-3198. 10.1182/blood-2009-03-207522, 2759647, 19667404.
45. Wallet MA, Sen P, Flores RR, Wang Y, Yi Z, Huang Y, Mathews CE, Earp HS, Matsushima G, Wang B, Tisch R. MerTK is required for apoptotic cell-induced T cell tolerance. J Exp Med 2008, 205:219-232. 10.1084/jem.20062293, 2234377, 18195070.
46. Rothlin CV, Ghosh S, Zuniga EI, Oldstone MB, Lemke G. TAM receptors are pleiotropic inhibitors of the innate immune response. Cell 2007, 131:1124-1136. 10.1016/j.cell.2007.10.034, 18083102.
47. Preble OT, Black RJ, Friedman RM, Klippel JH, Vilcek J. Systemic lupus erythematosus:presence in human serum of an unusual acid-labile leukocyte interferon. Science (New York) 1982, 216:429-431.
48. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, Shark KB, Grande WJ, Hughes KM, Kapur V, Gregersen PK, Behrens TW. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003, 100:2610-2615. 10.1073/pnas.0337679100, 151388, 12604793.
49. Aspinall AI, Curbishley SM, Lalor PF, Weston CJ, Liaskou E, Adams RM, Holt AP, Adams DH. CX(3)CR1 and vascular adhesion protein-1-dependent recruitment of CD16(+) monocytes across human liver sinusoidal endothelium. Hepatology (Baltimore) 2010, 51:2030-2039.
50. Garibaldi S, Barisione C, Ghigliotti G, Spallarossa P, Barsotti A, Fabbi P, Corsiglia L, Palmieri D, Palombo D, Brunelli C. Soluble form of the endothelial adhesion molecule CD146 binds preferentially CD16+ monocytes. Mol Biol Rep 2012, 39:6745-6752. 10.1007/s11033-012-1499-x, 22311021.
51. Ramirez R, Carracedo J, Merino A, Soriano S, Ojeda R, Alvarez-Lara MA, Martin-Malo A, Aljama P. CD14 + CD16+ monocytes from chronic kidney disease patients exhibit increased adhesion ability to endothelial cells. Contrib Nephrol 2011, 171:57-61.
52. Cederblad B, Blomberg S, Vallin H, Perers A, Alm GV, Ronnblom L. Patients with systemic lupus erythematosus have reduced numbers of circulating natural interferon-alpha-producing cells. J Autoimmun 1998, 11:465-470. 10.1006/jaut.1998.0215, 9802930.
53. Blomberg S, Eloranta ML, Cederblad B, Nordlin K, Alm GV, Ronnblom L. Presence of cutaneous interferon-alpha producing cells in patients with systemic lupus erythematosus. Lupus 2001, 10:484-490. 10.1191/096120301678416042, 11480846.
54. Tucci M, Quatraro C, Lombardi L, Pellegrino C, Dammacco F, Silvestris F. Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis:role of interleukin-18. Arthritis Rheum 2008, 58:251-262. 10.1002/art.23186, 18163476.
55. Zizzo G, Guerrieri J, Dittman LM, Merrill JT, Cohen PL. Circulating levels of soluble MER in lupus reflect M2c activation of monocytes/macrophages, autoantibody specificities and disease activity. Arthritis Res Ther 2013, 15:R212. 10.1186/ar4407, 24325951.
56. Choi JY, Park HJ, Lee YJ, Byun J, Youn YS, Choi JH, Woo SY, Kang JL. Upregulation of Mer receptor tyrosine kinase signaling attenuated lipopolysaccharide-induced lung inflammation. J Pharmacol Exp Ther 2013, 344:447-458. 10.1124/jpet.112.199778, 23197771.
57. Lee YJ, Lee SH, Youn YS, Choi JY, Song KS, Cho MS, Kang JL. Preventing cleavage of Mer promotes efferocytosis and suppresses acute lung injury in bleomycin treated mice. Toxicol Appl Pharmacol 2012, 263:61-72. 10.1016/j.taap.2012.05.024, 22687607.
58. McColl A, Bournazos S, Franz S, Perretti M, Morgan BP, Haslett C, Dransfield I. Glucocorticoids induce protein S-dependent phagocytosis of apoptotic neutrophils by human macrophages. J Immunol 2009, 183:2167-2175. 10.4049/jimmunol.0803503, 19597001.
59. Ehrchen J, Steinmuller L, Barczyk K, Tenbrock K, Nacken W, Eisenacher M, Nordhues U, Sorg C, Sunderkotter C, Roth J. Glucocorticoids induce differentiation of a specifically activated, anti-inflammatory subtype of human monocytes. Blood 2007, 109:1265-1274.
60. Brandao LN, Winges A, Christoph S, Sather S, Migdall-Wilson J, Schlegel J, McGranahan A, Gao D, Liang X, Deryckere D, Graham DK. Inhibition of MerTK increases chemosensitivity and decreases oncogenic potential in T-cell acute lymphoblastic leukemia. Blood Cancer J 2013, 3:e101. 10.1038/bcj.2012.46, 3556576, 23353780.
61. Keating AK, Salzberg DB, Sather S, Liang X, Nickoloff S, Anwar A, Deryckere D, Hill K, Joung D, Sawczyn KK, Park J, Curran-Everett D, McGavran L, Meltesen L, Gore L, Johnson GL, Graham DK. Lymphoblastic leukemia/lymphoma in mice overexpressing the Mer (MerTK) receptor tyrosine kinase. Oncogene 2006, 25:6092-6100. 10.1038/sj.onc.1209633, 16652142.